시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 비교리스트
세계의 동물용 통증 관리 시장 규모, 점유율, 산업 동향 분석 리포트 : 동물 유형별, 최종 용도별, 적응증별, 제품 유형별, 지역별 전망과 예측(2023-2030년)
Global Veterinary Pain Management Market Size, Share & Industry Trends Analysis Report By Animal type (Livestock Animal and Companion Animal), By End-Use, By Indication, By Product, By Regional Outlook and Forecast, 2023 - 2030
상품코드 : 1353569
리서치사 : KBV Research
발행일 : 2023년 08월
페이지 정보 : 영문 274 Pages
 라이선스 & 가격 (부가세 별도)
US $ 3,600 ￦ 5,208,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 4,320 ￦ 6,250,000
PDF (Multi User License) help
PDF 보고서를 동일 기업의 10명까지 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,048 ￦ 8,750,000
PDF (Corporate User License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


한글목차

동물용 통증 관리 시장 규모는 2030년까지 25억 달러에 달하며, 예측 기간 중 CAGR은 6.2%의 시장 성장률로 상승할 것으로 예측됩니다.

그러나 가축의 통증 치료에는 몇 가지 윤리적, 현실적인 문제가 있습니다. 사회 전체와 동물의 상충되는 요구는 법적으로도 분명합니다. 동물에게 진통제를 투여하는 법적 프레임워크는 마약과 같은 강력한 관리형 진통제가 적절하게 보관 및 관리되지 않을 경우 남용의 위험성 등 다양한 요소를 고려해야 합니다. 이처럼 통증 관리를 둘러싼 법적 문제는 향후 수년간 시장 확대에 부정적인 영향을 미칠 수 있습니다.

동물 종별 전망

동물 유형에 따라 시장은 가축과 반려동물로 분류됩니다. 반려동물은 2022년 시장에서 상당한 매출 점유율을 차지할 것으로 예상됩니다. 반려동물 소유자 수 증가, 인식 증가, 효과적인 동물 관리의 필요성이 이 부문의 성장에 기여하고 있습니다. 또한 비만과 암, 골관절염과 같은 만성질환의 발생률이 증가하면서 시장을 촉진하고 있습니다.

최종 용도 전망

최종 용도에 따라 시장은 병원 및 클리닉과 기타로 분류되며, 2022년에는 병원 및 클리닉 부문이 시장에서 가장 큰 매출 점유율을 차지할 것으로 예상됩니다. 이는 이러한 산업이 다양한 진단 및 치료 옵션을 제공하기 때문입니다. 외래 환자 요구와 외과수술 증가는 이 부문의 확장을 이끄는 주요 원동력입니다. 또한 동물병원은 현대적인 기술을 갖추고 있습니다.

적응증 전망

적응증별로 보면 시장은 골관절염, 수술 후 통증, 기타로 세분화됩니다. 수술 후 통증은 2022년 시장에서 두드러진 매출 점유율을 기록했습니다. 선진국과 신흥 국가 시장 모두에서 수의학 수술 건수가 증가하고 있는 것이 이 부문의 큰 비중을 차지하는 요인으로 추정됩니다. 수의 외과수술에 대한 수요는 반려동물의 치주질환 유병률 증가와 더 나은 치료 옵션의 필요성에 의해 주도되고 있습니다. 대부분의 동물은 수술 후 통증을 경험하기 때문에 동물용 통증 관리 제품의 사용이 촉진되고 있습니다.

제품 전망

제품별로는 비스테로이드성 항염증제(NSAIDs), 마취제, 오피오이드, 기타로 구분되며, 2022년에는 비스테로이드성 항염증제(NSAIDs) 시장이 가장 큰 매출 점유율을 차지할 것으로 예상됩니다. 이는 비스테로이드성 항염증제(NSAIDs)의 동물용 진통제 사용이 증가하고 있으며, NSAIDs는 골관절염 동물의 통증과 염증을 완화하는 데 널리 사용되고 있기 때문입니다. 주요 시장 참여자들은 기존 NSAIDs의 반응과 부작용을 줄이기 위해 완전히 새로운 NSAIDs를 개발하고 있습니다. 동물 소유주들은 동물에서 생산되는 유제품, 신선한 육류 및 영양 보충제에 대한 소비자 수요를 충족시키기 위해 일반 수의사 건강 기준을 준수해야 한다는 압박을 받고 있습니다. 동물용 비스테로이드성 항염증제의 사용은 향후 수년간 증가할 것으로 예상됩니다.

지역별 전망

지역별로 보면 북미, 유럽, 아시아태평양, LAMEA로 시장을 분석했으며, 2022년에는 북미가 시장에서 가장 높은 매출 점유율을 기록할 것으로 예상했습니다. 이는 반려동물 사육 증가와 우수한 동물 관리의 필요성 때문인 것으로 분석됩니다. 또한 잘 알려진 최첨단 동물 헬스케어 시설도 성장을 지원하고 있습니다. 북미의 동물용 처방전 필요성은 예측 기간 중 이 지역의 처방약 판매를 증가시킬 것으로 예상됩니다.

동물용 통증 관리 시장에서 펼쳐지는 전략

목차

제1장 시장 범위와 조사 방법

제2장 시장 개요

제3장 시장 개요

제4장 동물용 통증 관리 시장에서 도입되는 전략

제5장 세계의 동물용 통증 관리 시장 : 동물 유형별

제6장 세계의 동물용 통증 관리 시장 : 최종 용도별

제7장 세계의 동물용 통증 관리 시장 : 적응증별

제8장 세계의 동물용 통증 관리 시장 : 제품별

제9장 세계의 동물용 통증 관리 시장 : 지역별

제10장 기업 개요

제11장 동물용 통증 관리 시장의 성공 필수 조건

KSA
영문 목차

영문목차

The Global Veterinary Pain Management Market size is expected to reach $2.5 billion by 2030, rising at a market growth of 6.2% CAGR during the forecast period.

Obesity is the primary cause of joint issues in dogs, and it can also contribute to other orthopedic problems like hip dysplasia and arthritis pain. Thus, the Companion segment will register a 2/5th share of the market by 2030. Due to the additional pressure on bones, obesity in pet companions can cause various diseases of the bones and joints. In fatty and overweight animals, arthritis and ligament rips are prevalent and more severe. Compared to adult dogs, puppies are quite more prone to fractures. Additionally, the owner's capacity to spend on their pet's orthopedic operation and growing pet care awareness are fostering the market's expansion. Some of the factors impacting the market are increasing public concern for animal health and welfare, humanization trend and rising pet ownership, and legal issues in pain management.

The demand for these products has increased as a result of the increasing efforts taken by various governments in different areas. In the UK, pertinent cattle health and welfare issues tend to be resolved through the Cow Health and Welfare Group (CHAWG). The CHAWG is the first contact for inquiries relating to the welfare, health, and disease concerns currently impacting cattle. The makeup of CHAWG was a highly beneficial resource for the market because it offered a broad and in-depth range of information about cattle health and welfare. Therefore, this market is being driven by a rising number of initiatives undertaken by major businesses and government agencies. Globally, pet ownership is on the rise, especially in millennial households, inclined to be smaller families with children raised later in life. Pet lovers benefit the business and are anticipated to significantly contribute to market expansion during the forecast period. Many businesses are striving to provide superior pet care products in response to the rising demand for luxury pet products worldwide to acquire a significant share of the market. Given these factors, it is projected that as pet ownership and the humanization phenomenon increase, this will impact the market.

However, there are several ethical and practical issues in treating farm animals' pain. The conflicting needs of society as a whole and animals are apparent in a legal sense. Legislative frameworks for the administration of analgesic drugs to these animals need to consider various factors, such as the risk of abuse if powerful controlled analgesic drugs, like narcotics, are not properly stored and accounted for. Thus, the legal issues surrounding pain management could have a negative effect on the market's expansion in the coming years.

Animal type Outlook

By animal type, the market is classified into livestock animal and companion animal. The companion animal covered a considerable revenue share in the market in 2022. Their increased ownership, awareness, and need for effective animal care are responsible for the growth of the segment. Additionally, the incidence of obesity and other chronic diseases like cancer and osteoarthritis is rising, fueling the market.

End-Use Outlook

Based on end-use, the market is categorized into hospitals & clinics and others. In 2022, the hospitals and clinics segment witnessed the largest revenue share in the market. It is due to these verticals provide a wide range of diagnostic and treatment options. The need for outpatient facilities and increased surgical procedures are major growth drivers propelling the segment's expansion. Additionally, veterinary hospitals have modern technology.

Indication Outlook

On the basis of indication, the market is fragmented into osteoarthritis, post-operative pain, and others. The post-operative pain recorded a remarkable revenue share in the market in 2022. The growing number of veterinary surgeries in both developed and developing markets can be attributed to the significant proportion of this segment. The demand for veterinary surgery is driven by an increase in the prevalence of periodontal disease in pets and a need for better treatment alternatives. Most animals experience pain after surgery, prompting the use of veterinary pain management products.

Product Outlook

Based on product, the market is segmented into NSAIDs, anesthetics, opioids, and others. In 2022, the NSAIDs segment dominated the market with the maximum revenue share. This is due to the increased use of nonsteroidal anti-inflammatory drugs (NSAIDs) for animal analgesics. NSAIDs are widely used to relieve pain and inflammation in animals with osteoarthritis. The major market players are also creating brand-new NSAIDs to reduce the reactions and negative effects brought on by existing ones. Animal owners are under increasing pressure to adhere to the prevailing veterinarian health standards to meet consumer demand for dairy products, fresh meat, and dietary supplements generated from animals. The use of veterinary NSAIDs is anticipated to increase in the coming years.

Regional Outlook

Region-wise, the market is analysed across North America, Europe, Asia Pacific, and LAMEA. In 2022, the North America region generated the highest revenue share in the market. This is due to an increase in pet ownership and the need for superior animal care. Well-established and cutting-edge animal healthcare facilities are also supporting the growth. The requirement for veterinary prescriptions in North America is anticipated to increase prescription drug sales during the forecasted period in this region.

The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Boehringer Ingelheim International GmbH, Bayer AG, Zoetis, Inc., Merck & Co., Inc., Elanco Animal Health, Inc., Zomedica Corp. (Assisi Animal Health), Norbrook Laboratories Limited, Ceva Sante Animale, Dechra Pharmaceuticals PLC, and Vetoquinol SA (Soparfin SCA)

Strategy Deployed in Veterinary Pain Management Market

May-2023: Zoetis, Inc. got approval from the U.S. Food and Drug Administration (FDA) for Librela, an anti-NGF monoclonal antibody treatment for canine OA pain, is both safe and effective in reducing symptoms of the condition over the long term in dogs.

Sep-2022: Zoetis, Inc. completed the acquisition of NewMetrica, a company that offers scientifically validated tools to assess animal welfare. Through this acquisition, Zoetis would be better equipped to provide care along the entire continuum, increase knowledge of quality-of-life evaluations, and gain a deeper understanding of an animal's wellbeing.

Jun-2022: Zoetis, Inc. announced the acquisition of Basepaws, a company that develops early-warning health risk diagnostics for pets using genetic and microbiome information. With the addition of Basepaws, Zoetis would further bolster its line-up of solutions for precise animal health across genetics, diagnostics, and data analytics for domestic animals as well as farm animals.

Jan-2022: Zoetis, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved Solensia, an antibody therapy that controls the discomfort of feline osteoarthritis (OA), enhancing their mobility, comfort, and general well-being. Solensia's clearance is a significant advancement in the treatment of feline OA pain shown to manage OA discomfort and assist cats in regaining more mobility.

Jan-2022: Dechra Pharmaceuticals PLC signed an agreement to acquire Isoflurane and Sevoflurane from Halocarbon Life Sciences, a Pioneering company dedicated to developing cutting-edge medical technologies and advancing healthcare solutions. Through this acquisition, Dechra would be able to expand its portfolio, delivering quality products to the veterinary community. Moreover, these products would complement to their sedative and anesthetic range, fueling their growth in surgical solutions.

Jan-2022: Boehringer Ingelheim International GmbH came into collaboration with MabGenesis, a biopharmaceutical company that set out to create both human and animal therapeutic monoclonal antibodies. According to the agreement, MabGenesis would use its distinctive platform to find first-in-class candidate antibodies against targets of interest chosen by Boehringer Ingelheim. Moreover, the ability to create and market goods because of the agreement will belong to Boehringer Ingelheim.

Dec-2021: Elanco Animal Health, Inc. came into partnership with Morris Animal Foundation, an organization enhancing animal health through research and care. Through this partnership, would be able to create the essential tools needed for enhancing their capability to diagnose and monitor dogs affected with the conditions.

Sep-2021: Boehringer Ingelheim International GmbH signed a collaboration with Invetx, a business creating the leading animal health biotechnology innovation platform for protein-based therapies. Through this collaboration, both companies would create novel, species-specific monoclonal antibody (mAb) biotherapeutics that would initially target dogs and cats to treat a variety of veterinary species disorders.

Apr-2021: Elanco Animal Health, Inc. introduced Elura, a new CKD treatment for cats that tackles associated weight loss. Elura is a solution with an appealing taste and minimal dosage and is recommended to be initiated upon diagnosis. Moreover, this treatment can be continued over the long term, assisting pet owners in caring for their cats as they navigate the illness.

Jul-2019: Elanco Animal Health, Inc. completed the acquisition of Aratana Therapeutics, a company Pioneering pet treatments, enhancing well-being through innovative therapies for improved animal health. Through this acquisition, Aratana's robust standing in the specialized market, combined with its portfolio and upcoming projects, aligns and capabilities would be added to Elanco's pet therapy brands.

Scope of the Study

Market Segments covered in the Report:

By Animal type

By End-Use

By Indication

By Product

By Geography

Companies Profiled

Unique Offerings from KBV Research

Table of Contents

Chapter 1. Market Scope & Methodology

Chapter 2. Market at a Glance

Chapter 3. Market Overview

Chapter 4. Strategies Deployed in Veterinary pain management Market

Chapter 5. Global Veterinary Pain Management Market by Animal type

Chapter 6. Global Veterinary Pain Management Market by End-use

Chapter 7. Global Veterinary Pain Management Market by Indication

Chapter 8. Global Veterinary Pain Management Market by Product

Chapter 9. Global Veterinary Pain Management Market by Region

Chapter 10. Company Profiles

Chapter 11. Winning Imperative for Veterinary pain management Market

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기